TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02675920
Drug: non-ionic monomer iodinated CT contrast media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
Study: NCT01820195
Drug: Oral N-Acetyl Cystein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
Study: NCT01820195
Drug: IV N-Acetyl Cystein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
Study: NCT01820195
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group will be received both oral placebo and IV placebo
Study: NCT03591926
Drug: SM04646
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week.
Study: NCT00837200
Drug: Oncaspar, Doxil, Decadron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
Study: NCT02182934
Drug: Ginsana
Normalized name: Ginsana 200mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04247230
Drug: STUD100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
Study: NCT00666055
Drug: ARV regimen chosen by treating physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI).
Study: NCT04146038
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01418118
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
Study: NCT01418118
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
Study: NCT01470456
Drug: SAR3419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion Route of administration: Intravenous
Study: NCT02782286
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients randomised to this arm will receive 30 mg intravenous ketorolac.
Study: NCT02727907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
Study: NCT02515851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01098032
Drug: Systemic alone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
Study: NCT01587144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
Study: NCT03794180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
Study: NCT00382135
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth once a day for 40 weeks
Study: NCT03034915
Drug: UMEC/VI 62.5/25 mcg via ELLIPTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
Study: NCT03034915
Drug: UMEC 62.5 mcg via ELLIPTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
Study: NCT03034915
Drug: Placebo via ELLIPTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
Study: NCT03034915
Drug: Placebo via DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Study: NCT00714558
Drug: Fentanyl citrate; Naltrexone; Naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00534560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets; 4 week dose titration with 16 weeks at target dose
Study: NCT00424762
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: blinded treatment with matching placebo
Study: NCT00246012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
Study: NCT00853827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01673425
Drug: Live Attenuated Influenza Vaccine
Normalized name: Live attenuated influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be given FluMist.
Study: NCT03216395
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
Study: NCT03228992
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
Study: NCT00978237
Drug: LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills QD VO
Study: NCT00250341
Drug: Servent Diskus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg
Study: NCT00241722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03965013
Drug: NNC0268-0965
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
Study: NCT03965013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo given in Part 1
Study: NCT03117855
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02690350
Drug: U3-1784
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Study: NCT04339816
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally or into nasogastric tube for 5 days
Study: NCT04339816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally or into nasogastric tube for 5 days
Study: NCT02618317
Drug: Minocycline-EDTA 30 mg/ml - 3 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
Study: NCT02273661
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An aerosol of isotonic saline x 1/ week will be administered during 6 months
Study: NCT01716949
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
Study: NCT04981379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Study: NCT00786318
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haldol 5mg/ Ativan 2mg IM
Study: NCT01787240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00116623
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01640782
Drug: Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles.
Study: NCT01640782
Drug: Leucovorin, 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations.
Study: NCT01023373
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypotensive drugs, statins and anti-platelets
Study: NCT02386982
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04485156
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/kg
Study: NCT00427167
Drug: AMA1-C1/Alhydrogel + CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00137293
Drug: GAP-486 (ZP-123)
Normalized name: GAP JUNCTION ALPHA-3 PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00295542
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril)
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at awakening versus bedtime
Study: NCT01194154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
Study: NCT00295542
Drug: ARB (including valsartan, telmisartan, olmesartan)
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at awakening versus bedtime
Study: NCT03219645
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
Study: NCT00878722
Drug: PXD101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03369704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
Study: NCT00795704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg #2 capsules by mouth three times daily
Study: NCT03674294
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
Study: NCT04347954
Drug: Isotonic saline 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
Study: NCT01113333
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study: NCT01113333
Drug: SAR113945
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study: NCT00197886
Drug: Changing dose of norepinephrine and blood pressure
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00310089
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01149525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution, twice per day (morning/evening), during 3 months
Study: NCT00367991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline to match active drug (rHuEpo)
Study: NCT01733238
Drug: PNT2258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00748306
Drug: GSK2190915 - 100mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
Study: NCT00748306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Intervention Drug
Study: NCT00310089
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00790790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 placebo BID po for 5 weeks
Study: NCT00790790
Drug: LY545694 49 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 49 mg BID po for 5 weeks.
Study: NCT00790790
Drug: LY545694 105 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 105 mg BID po for 5 weeks.
Study: NCT03897348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication
Study: NCT02880241
Drug: MMV390048
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of 20mg each
Study: NCT00165451
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration twice daily starting at 100mg/dose for 6 months.
Study: NCT00165451
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
Study: NCT03920215
Drug: OC-01 Low Dose, 0.12 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline) nasal spray
Study: NCT03920215
Drug: OC-01 Mid Dose, 0.6 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline) nasal spray
Study: NCT03920215
Drug: OC-01 High Dose, 1.2 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline) nasal spray
Study: NCT03920215
Drug: Placebo (vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) nasal spray
Study: NCT01802866
Drug: ACU-4429
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take orally once daily for 24 months
Study: NCT01802866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take orally once daily for 24 months
Study: NCT02625467
Drug: Treatment posterior to surgery
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
Study: NCT01160224
Drug: GW766944
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GW766944 (Active Drug Treatment)
Study: NCT00407641
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Heparin as an anticoagulant during the HD session.
Study: NCT01600105
Drug: Perfusion MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
Study: NCT03052361
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: similar looking and tasting liquid placebo
Study: NCT02104765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously.
Study: NCT01970618
Drug: RV1162 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single escalating doses
Study: NCT01970618
Drug: RV1162 matching placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single escalating doses
Study: NCT01970618
Drug: RV1162: 7 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of a repeat dose
Study: NCT01970618
Drug: RV1162 matching placebo: 7 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of a repeat dose
Study: NCT01970618
Drug: RV1162: 14 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat escalating doses
Study: NCT01970618
Drug: RV1162 matching placebo: 14 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat escalating doses
Study: NCT00305591
Drug: l-ornithine l-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02613806
Drug: Dexmeditomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
Study: NCT02613806
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
Study: NCT00028964
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03008018
Drug: KA2507
Approvals — FDA: no, EMA: no, PMDA: no
Description: KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
Study: NCT00028964
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02876484
Drug: Chenodeoxycholic Acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00509535
Drug: vitreoscilla filiformis cream
Normalized name: Vitreoscilla lysate extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02805894
Drug: NBTXR3 activated by IMRT only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
Study: NCT02805894
Drug: NBTXR3 activated by Brachytherapy & IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
Study: NCT05076656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a white, gelatin capsule (orally), with powder milk
Study: NCT01385657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 4 doses were administered.
Study: NCT01582399
Drug: ASKP1240
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous(IV) infusion and subcutaneous (SC)
Study: NCT00688519
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
Study: NCT02101190
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone, OPC
Study: NCT00009646
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
Study: NCT00009646
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mg per kilogram of body weight
Study: NCT00009646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg per kilogram of body weight
Study: NCT00003549
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003549
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes